9 research outputs found
Bilateral Peroneal Neuropathy after Obesity Surgery
A 33-year-old woman is presented with a bilateral progressive foot drop in three months. Her medical history revealed an obesity surgery seven months ago and she had 65 kgs weight loss in about six months (from 147 kgs to 82 kgs). Bilateral peroneal neuropathy determined at the fibular head on her electromyography study. The case highlights the importance of paying attention to the peroneal neuropathy after massive weight loss. Diet modification and physical therapy should be kept in mind in these patients
Hepatocellular Carcinoma and Liver Transplantation: A Single-Center Experience
Conclusion. A transplant decision is controversial in patients with HCC with other than previously defined morphologic criteria. In these cases, AFP level and histologic differentiation determine survival. The results were not satisfactory in both high and/or poorly differentiated cases
The Clinical Characteristics and Therapeutic Outcomes of Elderly Patients with Chronic Lymphocytic Leukemia: A Retrospective Multicenter Study
56th Annual Meeting of the American-Society-of-Hematology -- DEC 06-09, 2014 -- San Francisco, CAWOS: 000349233802125Amer Soc Hemato
A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP)
A Multi-Center Study on the Efficacy of Eltrombopag in Management of Refractory Chronic Immune Thrombocytopenia: A Real-Life Experience
Objective: The aim of the present study was to evaluate the efficacy and
safety of eltrombopag, an oral thrombopoietin receptor agonist, in
patients with chronic immune thrombocytopenia (ITP).
Materials and Methods: A total of 285 chronic ITP patients (187 women,
65.6 \%; 98 men, 34.4\%) followed in 55 centers were enrolled in this
retrospective cohort. Response to treatment was assessed according to
platelet count (/mm(3)) and defined as complete (platelet count of
>100,000/mm(3)), partial (30,000-100,000/mm(3) or doubling of platelet
count after treatment), or unresponsive (<30,000/mm(3)). Clinical
findings, descriptive features, response to treatment, and side effects
were recorded. Correlations between descriptive, clinical, and
hematological parameters were analyzed.
Results: The median age at diagnosis was 43.9 +/- 20.6 (range: 3-95)
years and the duration of follow-up was 18.0 +/- 6.4 (range: 6-28.2)
months. Overall response rate was 86.7\% (n=247). Complete and partial
responses were observed in 182 (63.8\%) and 65 (22.8\%) patients,
respectively. Thirty-eight patients (13.4\%) did not respond to
eltrombopag treatment. For patients above 60 years old (n=68), overall
response rate was 89.7\% (n=61), and for those above 80 years old
(n=12), overall response rate was 83\% (n=10). Considering thrombocyte
count before treatment, eltrombopag significantly increased platelet
count at the 1st, 2nd, 3rd, 4th, and 8th weeks of treatment. As the time
required for partial or complete response increased, response to
treatment was significantly reduced. The time to reach the maximum
platelet levels after treatment was quite variable (1-202 weeks).
Notably, the higher the maximum platelet count after eltrombopag
treatment, the more likely that side effects would occur. The most
common side effects were headache (21.6\%), weakness (13.7\%),
hepatotoxicity (11.8\%), and thrombosis (5.9\%).
Conclusion: Results of the current study imply that eltrombopag is an
effective therapeutic option even in elderly patients with chronic ITP.
However, patients must be closely monitored for response and side
effects during treatment. Since both response and side effects may be
variable throughout the follow-up period, patients should be evaluated
dynamically, especially in terms of thrombotic risk factors